Invited Editorial: Advantages and Limitations of FAERS in Assessing Adverse Event Reporting for Eluxadoline

Ítems similars

• Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
  per: Zhuomiao Lin, et al.
  Publicat: (2025-08-01)
• Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).
  per: Yuzhe Cheng, et al.
  Publicat: (2025-01-01)
• Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
  per: Yuzhe Cheng, et al.
  Publicat: (2025-01-01)
• Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
  per: Chengzhi Liu, et al.
  Publicat: (2024-12-01)
• A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil
  per: Yun Li, et al.
  Publicat: (2025-01-01)